Seres Therapeutics (MCRB) PT Lowered to $32 at Piper Sandler, Following Clinical Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts MCRB Hot Sheet
Price: $2.09 --0%
Rating Summary:
9 Buy, 3 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 6
Rating Summary:
9 Buy, 3 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 6
Join SI Premium – FREE
Piper Sandler analyst Edward A. Tenthoff lowered the price target on Seres Therapeutics (NASDAQ: MCRB) to $32.00 (from $40.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Seres Therapeutics (MCRB) Tops Q3 EPS by 1c
- Peabody Energy (BTU) PT Lowered to $26 at StoneX
- Dutch Bros Inc. (BROS) PT Lowered to $55 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Edward TenthoffSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
